

TITLE PAGE

Protocol Number: C-17-EV12

Protocol Title: Open-label, Prospective, Single-Center Feasibility Study to Evaluate the Cutera excel V™ Laser with Green Genesis and a Micro-Lens Array Attachment as compared to the standard-of-care with an excel V™ Laser

Sponsor: Cutera, Inc.
3240 Bayshore Boulevard
Brisbane, CA 94005
Telephone: 1-415-657-5538
Fax: 1-415-715-3722
Contact: Matthew Hammond
Email: mhammond@cutera.com

Version, Date: Version 1.0, Dated: November 6th, 2017

Statement of Compliance

The study will be conducted in accordance with the design and specific provisions of this IRB approved protocol, in accordance with the ethical principles that have their origin in the Declaration of Helsinki, and that are consistent with Good Clinical Practice (GCP) and the applicable regulatory requirement(s).

NOTE: The confidential information in the following document is provided to you as an Investigator, potential Investigator, or consultant for review by you, your staff, and applicable Institutional Review Board. By accepting this document, you agree that the information contained herein will not be disclosed to others, without written authorization from Cutera, Inc. except to the extent necessary to obtain informed consent from those persons to whom the device will be administered.

Protocol Signature Sheet – Principal Investigator

PROTOCOL C-17-EV12

Study Title: Open-label, Prospective, Single-Center Feasibility Study to Evaluate the Cutera excel V™ Laser with Green Genesis and a Micro-Lens Array Attachment as compared to the standard-of-care with an excel V™ Laser

Protocol Version 1.0, Date: November 6th, 2017

I have received and read the protocol dated November 6th, 2017 and agree to adhere to the requirements. I am aware that my adherence to the above protocol is mandatory and that any changes in the protocol or informed consent form must first be approved by Cutera, Inc. and the Institutional Review Board, except those changes necessary to eliminate apparent immediate hazards to subjects. I will provide copies of this protocol and all pertinent information to the study personnel under my supervision. I will discuss this material with them and ensure they are fully informed regarding their role in the study. I will ensure that the study is conducted in compliance with the protocol, Good Clinical Practice (GCP), and all applicable regulatory requirements, and with the reviewing Institutional Review Board (IRB) requirements. I agree to commence this study only after documented IRB approval is obtained.

Principal
Investigator

Signature

Date

Printed Name

Date

TABLE OF CONTENTS

<u>1. BACKGROUND INFORMATION</u>	Error! Bookmark not defined.
<u>2. STUDY DEVICE</u>	6
<u>3. STUDY OBJECTIVES</u>	7
<u>4. Study Design and Endpoints</u>	7
4.1. Primary Endpoint	7
4.1.2 Secondary Endpoints	8
4.1.3 Exploratory Analysis	8
4.2 Study Duration	8
4.3 Study Effectiveness Assessments	8
4.3.1 Investigator Assessments	8
4.3.2 Subject Satisfaction Assessment	10
4.4 Study Safety Assessments	10
4.4.1 Incidence and Severity of Adverse Events:	10
4.4.2 Treatment-related Discomfort	10
4.4.3 Phone Follow-up	10
4.5 Photographs	10
4.6 Study Discontinuation	11
4.7 Investigator Selection	11
<u>5. STUDY POPULATION</u>	11
5.1 Study Subject Recruitment and Selection	11
5.1.1 Inclusion Criteria	11
5.1.2 Exclusion Criteria	12
5.2 Subject Numbering	13
5.3 Subject Discontinuation Criteria	13
6. STUDY PROCEDURES	13
6.1 Screening / Enrollment	13
6.2 Laser Treatment Visits 1 to 5 – Visit Window and Pre-Treatment Procedures	15
6.3 Laser Treatment Procedures	16
6.4 Phone and Follow-Up Visits	16
6.5 Evening Laser Treatment Visits (up to 2)	17
<u>7. ADVERSE EVENTS and ADVERSE DEVICE EFFECTS</u>	18
7.1 Definitions	18
7.1.1 Adverse Event	18
7.1.2 Serious Adverse Event	18
7.1.2.1 Anticipated Serious Adverse Device Events	19
7.1.2.2 Unanticipated Serious Adverse Device Events	19
7.2 Recording AEs, EADEs, ADEs and SAEs	21
7.3 Follow-up of subjects after AEs/ADEs and SAEs/SAEs:	21



<u>8. POTENTIAL RISKS / BENIFITS</u>	21
<i>8.1 Potential Risks</i>	21
<i>8.2 Potential Benefits</i>	22
<u>9. RISK MANAGEMENT</u>	22
<u>10. DATA ANALYSIS PLAN</u>	23
<i>10.1 Sample Size</i>	23
<i>10.2 Statistical Analysis Methods</i>	23
11. SUBJECT PAYMENT	23
<u>12. STUDY MANAGEMENT AND ADMINISTRATIVE PROCEDURES</u>	23
<i>12.1 Training and Monitoring</i>	23
<i>12.2 Informed Consent</i>	23
<i>12.3 Protocol Compliance</i>	24
<i>12.4 Protocol Amendments</i>	24
<i>12.5 Protocol Deviations</i>	24
<i>12.6 Study Personnel</i>	24
<i>12.7 Disclosure of Financial Interest</i>	24
<i>12.8 Data Collection, Record Keeping and Storage</i>	25
<u>13. SUBJECT CONFIDENTIALITY</u>	25
<u>14. PUBLICATION POLICY</u>	26
Appendix 1: Study Schedule	29
Appendix 2: Pain Rating Scale	30
Appendix 3: Follow-Up Subject Questionnaire	32
Appendix 4: Fitzpatrick Skin Type Classification	33
Appendix 5: Befor and After Treatment Instructions	34
Appendix 6: Subject Spilt-Face Treatment Paramerters	35

Protocol Summary

Title	Open-label, Prospective, Single-Center Feasibility Study to Evaluate the Cutera excel V™ Laser with Green Genesis and a Micro-Lens Array Attachment as compared to the standard-of-care with an excel V™ Laser
Objective	<ol style="list-style-type: none"> To evaluate the safety and efficacy of the Cutera excel V laser and the Micro-Lens Array attachment to the Genesis V hand piece. To evaluate the safety and efficacy of the Cutera excel V laser Green Genesis V hand piece to the CoolView hand piece.
Study Design	Open-label, Prospective, Split-Face Study to Evaluate the Cutera excel V laser with Green Genesis (532 nm in a low fluence, high repetition rate mode) and the Micro-Lens Array attachment used with excel V laser at 1064 nm and/or 532 nm for the improvement of skin quality.
Enrollment	Approximately 30 subjects will be treated
Primary Endpoint	<ul style="list-style-type: none"> Safety of the Cutera excel V laser with Green Genesis assessed by frequency and severity of number of device adverse events as reported up to the 12 week follow-up visit. Safety of the Cutera excel V laser with Micro-Lens Array attachment assessed by frequency and severity of number of device adverse events as reported up to the 12 week follow-up visit. Efficacy of the Cutera excel V laser with the Micro-Lens Array to treat [REDACTED] Efficacy of the Cutera excel V laser with Green Genesis t [REDACTED]
Secondary Endpoints	[REDACTED]
Exploratory Analysis	<ul style="list-style-type: none"> [REDACTED] The improvement of ≥ 1 point on the Global Aesthetic Improvement Scale (GAIS) [REDACTED]
Subject Population	Female or male subjects, age 18 to 65 years, Fitzpatrick skin types I-VI
Estimated Planned Schedule	<p>First subject enrolled: November 2017</p> <p>Last subject last visit: July 2019</p>

1. BACKGROUND INFORMATION

Non-invasive treatment options are in high demand by patients wanting to improve their appearance without surgical intervention. As a result, patients now have a variety of options for non-invasive skin rejuvenation, from laser and light-based treatments to devices that utilize ultrasound and radiofrequency, however this was not always the case. Conventional treatment of dyschromia pigmentation disorders and rosacea have primarily been treated by external application of topical agents such as hydroquinone and azelaic acid, respectively [1,2]. Dyschromia and diffuse redness can also be treated by lasers of various wavelengths for correcting skin tone heterogeneity based on the principle of selective photothermolysis, whereby the laser wavelength is matched to the light absorption spectra of the target chromophore such as hemoglobin in blood vessels or melanin in pigment-producing skin cells [3, 4]. Absorption of laser light by these molecular chromophores results in the production of heat, leading to the ablative destruction of unwanted blood vessels and pigment cells. However, since ablative treatments destroy the epidermal layer of the skin in order to penetrate and heat the deeper dermal layers, ample post-procedure recovery time is required and patients may experience side effects lasting for a few weeks. Furthermore, hypo- or hyperpigmentation, prolonged wound healing and even scarring can occur following ablative laser treatments [5-7]. Treatment methods with less risk of side effects and post-treatment down time are in high demand. As such, the choices are vast and varied, ranging from fractional non-ablative laser devices to those that use radiofrequency [8-15]. Fractional lasers inflict microscopic zones of thermal damage in the dermal layers of the skin without destruction of the epidermis, thereby reducing recovery time significantly as compared to ablative procedures[16]. Treatment with non-fractional, non-ablative laser devices requires little to no post-procedure recovery time. In addition, the micro-thermal damage zones and heating within the dermis results in immediate collagen contraction and heat-induced wound healing that, over time, causes a cascade of cellular events leading to new collagen production and improved skin appearance [17-18].



2. STUDY DEVICE



Manual for this device.

3. STUDY OBJECTIVES

The objectives of this feasibility study are:

- a. To evaluate the safety and efficacy of the Cutera excel V laser and the Micro-Lens Array attachment to the Genesis V hand piece.
- b. To evaluate the safety and efficacy of the Cutera excel V laser Green Genesis V hand piece to the CoolView hand piece.

This is an open-label, prospective, split-face study in approximately 30 male or female subjects, age 18 to 65 years who desire laser treatment for the improvement of diffused redness, dyschromia (pigment), fine lines and texture, and acne scars.

Subjects will receive laser treatment visits, spaced 2 weeks) apart, and will be followed at visit, and at 12 weeks) following the final laser treatment.

4 Study Design and Endpoints

4.1. Primary Endpoint

- Safety of the Cutera excel V laser with Green Genesis assessed by frequency and severity of number of device adverse events as reported up to the 12 week follow-up visit.
- Safety of the Cutera excel V laser with Micro-Lens Array attachment assessed by frequency and severity of number of device adverse events as reported up to the 12 week follow-up visit.
- Efficacy of the Cutera excel V laser with the Micro-Lens Array to treat fine lines and skin texture, and/or the improvement of acne scars as compared to the SOC procedure using excel V, as assessed by the study investigator at the 12 week follow-up visit.
- Efficacy of the Cutera excel V laser with Green Genesis to diffuse facial redness and/or improve dyschromia (pigment) as compared to the Standard-of-Care (SOC), as assessed by the study investigator at the 12 week follow-up visit.

4.1.2.

■

4.1.3

■

- The improvement of ≥ 1 point on the Global Aesthetic Improvement Scale (GAIS) as assessed by up to three blinded assessors in at least 75% of subjects.

4.2 Study Duration

Subjects enrolled in this trial will participate for approximately 12 months, [REDACTED]. One screening and enrollment visit, [REDACTED], spaced 2 weeks [REDACTED]. Subjects will have [REDACTED] follow-up visits, [REDACTED], and second at 12 weeks [REDACTED] following the final laser treatment visit.

4.3 Study Effectiveness Assessments

4.3.1 Investigator Assessments

Baseline photos of subjects may be used while assessing the GAIS, [REDACTED]

[REDACTED] at the 12 week follow-up visit the Investigator will assess the efficacy of the Cutera excel V laser with GG and the MLA attachment treatment using the Global Aesthetic Improvement Scale (GAIS), [REDACTED].

Global Aesthetic Improvement Scale (GAIS):

4 = Very Significant Improvement [REDACTED]

3 = Significant Improvement ([REDACTED])

2 = Moderate Improvement ([REDACTED])


1 = Mild Improvement [REDACTED]

0 = No Change [REDACTED]

Cutera, Inc.

Protocol # C-17-EV12

“Open-label, Prospective, Single-Center Feasibility Study to Evaluate the Cutera excel V™ Laser with Green Genesis and a Micro-Lens Array Attachment as compared to the standard-of-care with an excel V™ Laser”



[REDACTED]		[REDACTED]	
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]

[REDACTED]

[REDACTED]

4.4 Study Safety Assessments

4.4.1 Incidence and Severity of Adverse Events:

Following the first laser treatment, adverse effects (AEs) will be assessed post-treatment and at each subsequent visit using the following scale:

- 1= mild: requires minimal or no treatment and does not interfere with the subject’s daily activities.
- 2= moderate: may cause some interference with functioning.
- 3= severe: interrupts subject’s usual daily activity and may require treatment.

4.4.2 Treatment-related Discomfort

After each laser treatment, subjects will be asked to rate the average amount of discomfort experienced during treatment and immediately after laser treatment.

[REDACTED]

[REDACTED]

4.5 Photographs

Standardized digital photographs will be taken of each subject’s treatment area at baseline, prior to and post all laser treatments and at follow-up visits. Treatment area will be cleansed and any jewelry and make-up will be removed from the area being photographed. For facial photographs, hair will be pulled away from the face with a headband.

Facial photographs will be obtained from at least 3 angles: with the subject facing forward, 45° to the right and 45° to the left. Photographs will be taken in the same windowless room equipped with adequate lighting. The room lighting, camera positioning and subject positioning should be consistent for all study visit photographs. Digital camera settings should remain the same for all photographs and the highest resolution settings should be utilized.

4.6 Study Discontinuation

Cutera, Inc. (the sponsor) has the right to terminate this study at any time. Reasons for terminating the study may include, but are not limited to, the following: incidence or severity of adverse events in this or other studies indicates a potential health hazard to subjects; subject enrollment is unsatisfactory; number of protocol deviations is unacceptable; data recording is inaccurate or incomplete; or questionable study site compliance with ICH-E6, Good Clinical Practice²³.

4.7 Investigator Selection

The Investigator(s) will be invited to participate in the study based on his or her medical specialty, experience conducting clinical research studies and experience in the use of light-based devices for aesthetic indications. Access to potential study subjects and the Investigator's sincere interest in this study along with expressed willingness to cooperate with the study process and requirements was also considered.

5. STUDY POPULATION

5.1 Study Subject Recruitment and Selection

Approximately 30 male or female subjects, ages 18 to 65, with Fitzpatrick Skin Type I-VI who desire laser treatment for the improvement of diffused redness, dyschromia (pigment), fine lines and texture, and acne scars. Subjects will be recruited to participate from the local population. Subjects may also be recruited from the Investigator's existing patient database or from patients who present themselves to the study site requesting treatment. Only subjects who meet all eligibility criteria and who provide written informed consent will be enrolled into the study.

Each subject will be evaluated by the Investigator/Sub-Investigator to assess his/her suitability for entry into the study according to the following inclusion and exclusion criteria.

5.1.1 Inclusion Criteria

To be included in the study, subjects must meet all of the following Inclusion Criteria:

1.	Subject must be able to read, understand and sign the Informed Consent Form.
2.	Female or Male, 18 to 65 years of age (inclusive).
3.	Fitzpatrick Skin Type I – VI.
4.	Must be willing to have Cutera excel V laser treatments with MLA and/or Green Genesis (532 nm) and able to adhere to the treatments, follow-up visit schedule, and post-treatment care instructions.
5.	Willing to have very limited sun exposure and use sunscreen on the treatment area every day for the duration of the study, including the follow-up period.
6.	Willing to have digital photographs taken of the treatment area and agree to use of photographs for presentation (educational and/or marketing), publications, and any additional marketing purposes.
7.	Agree to not undergo any other cosmetic procedure(s) or treatment(s) on the face during the study and has no intention of having such procedures performed during the course of the study.
8.	For female subjects: not pregnant or lactating and is either post-menopausal, surgically sterilized, or using a medically acceptable form of birth control at least 3 months prior to enrollment and during the entire course of the study.,

5.1.2 Exclusion Criteria

Subjects will be excluded from the study if they meet any of the following Exclusion Criteria:

1.	Participation in a clinical trial of another drug, or device administered to the treatment area, within 3 months prior to enrollment or during the study.
2.	Any type of prior cosmetic treatment to the target area within 3 months of study participation, such as laser procedures, facial fillers, toxins and those used for general aesthetic correction.
3.	Use of prescription topicals in the treatment area within one month prior to treatment or use of topical agents one week prior to treatment that may cause facial sensitivity.
4.	Suffering from significant skin conditions in the treated areas or inflammatory skin conditions, including but not limited to, open lacerations or abrasions, hidradenitis, rash, infection, or dermatitis of the treatment area prior to treatment (duration of resolution as per the Investigator's discretion).
5.	Pregnant and/or breastfeeding, or planning to become pregnant.
6.	Significant concurrent illness, such as diabetes mellitus, immunosuppression/immune deficiency disorders (including HIV infection or AIDS) or using immunosuppressive medication.
7.	Hypersensitivity to light exposure.
8.	Any use of medication that is known to increase sensitivity to light according to the Investigator's discretion.
9.	History of keloid scarring, hypertrophic scarring or abnormal wound healing or prone to bruising.
10.	Has a history of squamous cell carcinoma or melanoma in the treatment area.
11.	History of epidermal or dermal disorders (particularly if involving collagen or microvasculature), including collagen vascular disease or vasculitic disorders.
12.	A history or active skin condition that in the opinion of the Investigator may interfere/confound with the treatment.
13.	History of connective tissue disease, such as systemic lupus erythematosus or scleroderma.
14.	History of disease stimulated by heat, such as recurrent herpes simplex and/or herpes zoster (shingles) in the treatment area, unless treatment is conducted following a prophylactic regimen.
15.	History of pigmentary disorders, particularly tendency for hyper- or hypo-pigmentation, or any that are considered not acceptable by the study investigator.
16.	Has used oral isotretinoin (Accutane or therapeutic vitamin A supplements of $\geq 10,000$ units per day) within 12 months of initial treatment or plans on using during the course of the study (note: skin must regain its normal degree of moisture prior to treatment, e.g. lack of noticeable skin flaking and peeling).
17.	Excessively tanned or active sun tan in facial area to be treated, or unable/unlikely to refrain from tanning during the study.
19.	Excessive facial hair in the area to be treated (beards, sideburns, and/or moustache,) that would interfere with diagnosis, assessment, and treatment.
20.	As per the Investigator's discretion, any physical or mental condition which might make it unsafe for the subject to participate in this study, including excessive alcohol or drug abuses, or a condition that would compromise the subject's ability to comply with the study requirements.

5.3 Subject Discontinuation Criteria

In addition, a subject can be discontinued for any of the following reasons: the Principal Investigator decides that continuing in the study would not be in the subject's best interest, a subject is noncompliant with the protocol, a subject has a serious reaction to the treatment, a subject develops any of the exclusion criteria during the study period or the study is stopped by the study sponsor.


6. STUDY PROCEDURES

Version 1.0; 06Nov17

Cutera, Inc.

Protocol # C-17-EV12

“Open-label, Prospective, Single-Center Feasibility Study to Evaluate the Cutera excel V™ Laser with Green Genesis and a Micro-Lens Array Attachment as compared to the standard-of-care with an excel V™ Laser”



[REDACTED]

[REDACTED]

6.4 Phone and Follow-Up Visits

[REDACTED]

[REDACTED] and 12 weeks [REDACTED] following the final laser treatment visit.

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

7. ADVERSE EVENTS and ADVERSE DEVICE EFFECTS

7.1 Definitions

7.1.1 Adverse Event

[REDACTED]

[REDACTED]

7.1.2 Serious Adverse Event

[REDACTED]

- [REDACTED]
 - i [REDACTED]

[REDACTED]


[REDACTED]


[REDACTED]

Cutera, Inc.

Protocol # C-17-EV12

“Open-label, Prospective, Single-Center Feasibility Study to Evaluate the Cutera excel V™ Laser with Green Genesis and a Micro-Lens Array Attachment as compared to the standard-of-care with an excel V™ Laser”





7.2 Recording AEs, EADEs, ADEs and SADEs

All AEs/SAEs or EADEs/ADEs/SADEs will be: (1) evaluated and must be recorded in the subject's study case report forms (CRFs); (2) monitored and tracked from the time of the first treatment with the Cutera excel V laser system.

At each contact with the subject, the investigator must seek information on AEs/EADEs/ADEs/SADEs by specific questioning and, as appropriate, by examination. AEs/ADEs/SADEs may be observed by the investigator and/or clinical research staff, elicited from the subject and/or family member or volunteered by the subject. All observed and volunteered adverse signs and symptoms, anticipated or unanticipated, regardless of severity or frequency, will be recorded in the case histories (medical chart and CRFs). Included in the description should be the nature of the sign or symptom, the date of onset, date of resolution (duration), the severity, anticipated or unanticipated, the relationship to study treatment or other therapy, the action taken (if any), and the outcome.

All SAEs/SADEs, anticipated or unanticipated, must be reported to Cutera immediately but not later than 5 working days. The SADE must be recorded in: (1) the AE CRF and (2) a written report must be submitted to Cutera within five (5) working days after the investigator first learns of the event and is to include a full description of the event and sequelae, in the format detailed by the Cutera Serious Adverse Event Form.

7.3 Follow-up of subjects after AEs/ADEs and SAEs/SADEs:

All reported AEs/ADEs/SAEs/SADEs should be followed until resolution or until the subject's participation in the study ends. Resolutions of AEs/ADEs/SAEs/SADEs are to be documented on the appropriate CRFs. All ADEs that result in permanent discontinuation from this clinical trial, whether serious or not, should also be reported on the subject Non-Completion of Study Form.

8. POTENTIAL RISKS / BENIFITS

[REDACTED]

[REDACTED]			
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]

[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]

- [REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

8.2 Potential Benefits

The subjects may or may not benefit from the treatment with the study device. Potential benefit of laser treatment is improved in the appearance of the skin. There is no guarantee of success.

9. RISK MANAGEMENT

The investigator participating in this study was chosen based on extensive and safe experience with the use of lasers in dermatology applications. This is the most critical element in managing subject risk. In addition, study investigators will be trained on the use of the Cutera excel V laser system by a representative of Cutera.

10. DATA ANALYSIS PLAN

10.1 Sample Size

The planned sample size of approximately 30 subjects has been deemed sufficient for the evaluation of the Cutera excel V laser with the Green Genesis and the Micro-Lens Array attachment to the Coolview handpiece.

10.2 Statistical Analysis Methods

This is a study to evaluate safety and efficacy of the Cutera excel V laser with the Green Genesis and the Micro-Lens Array attachment to the Coolview handpiece. Outcome measures will be assessed around multiple endpoints. These measures will be: degree of improvement as assessed by the Investigator, [REDACTED] and safety. Formal hypothesis testing and statistical analysis are not planned for this study.

10.3 Safety Analyses

Safety variables will be analyzed descriptively. The safety variables for this study are:

- Incidence and severity of adverse effects during study duration (to be displayed descriptively as counts and frequency distributions)

Enrolled subjects who received at least one treatment will be included in the safety analyses. Device-related and procedure-related adverse effects (AEs) and subjects who prematurely terminate from the study due to an adverse device effect, including the treatment-related pain ratings, as reported on case report forms will be tabulated and analyzed. For a given AE term, counting will be done by subject, not by event, i.e. for a subject reporting the same AE more than once, the event will be counted only once, at the most severe and most-related occurrence. The number and percentage of subjects experiencing each AE Term will be descriptively summarized. Statistical hypothesis testing will not be performed for safety data.

[REDACTED]

12. STUDY MANAGEMENT AND ADMINISTRATIVE PROCEDURES

[REDACTED]

[REDACTED]

study records.

[REDACTED]

12.3 Protocol Compliance

The principal investigator must comply with all terms of the protocol.

12.4 Protocol Amendments

Neither the principal investigator nor the sponsor will modify or alter this protocol without first obtaining the concurrence of the other party (with the exception of amendments which involves mitigating a medical emergency or immediate health risk to the subject). The party initiating an amendment must confirm it clearly in writing and it must be signed and dated by the sponsor and the principal investigator. IRB approval must be obtained before implementation of an amendment.

12.5 Protocol Deviations

All protocol deviations must be clearly described on the case report form (i.e., Cutera Protocol Deviation Form). Deviations from the protocol may include but are not limited to subject's failure to attend scheduled visit during a visit window, use of out of range treatment parameters and incomplete or incorrect study procedures. Any medical emergency or immediate health risk to the subject which results in a protocol deviation and must be reported to the sponsor within 5 working days.

Significant protocol deviations must be reported to IRB according to their policies.

12.6 Study Personnel

The investigator must supply the sponsor with a list of the names and curricula vitae that describe the professional backgrounds of the clinically responsible study investigators (principal, sub-investigators), research nurses, and other possible participants (e.g. medical doctor, nurse, etc.).

12.7 Disclosure of Financial Interest

Each investigator [principal and sub-investigator(s)] is required to disclose sufficient accurate financial information to the sponsor, to allow sponsor to submit complete and accurate certification or disclosure

statements.

12.8 Data Collection, Record Keeping and Storage

The principal investigator is responsible for assuring that all study records including case report forms (CRFs), informed consent forms, device accountability records, source documents (e.g., notes, medical records, lab/histology reports etc.) and other study records are complete, accurate and recorded in a timely manner. For the study, CRFs will be considered source documents. All study data will be captured on the CRFs.

All data entries on the CRFs will be recorded completely, promptly, and legibly using blue or black indelible ink pen and accuracy will be ensured. The corrections on CRFs will be made only by the investigator or the documented investigator's designee. To make a correction to an entry, the data will be crossed through with a single line (the original entry should be visible) and then will be initialed and dated by the person making the correction.

The study records will be maintained in a secure location throughout the duration of the study. Upon study completion or termination, records will be kept at a secure location until at least 2 years after the last approval of a marketing application and until there are no pending or contemplated marketing applications or at least 2 years have elapsed since the formal discontinuation of clinical development of the investigational product.

13. SUBJECT CONFIDENTIALITY

This study preserves the confidentiality of all subjects under the Health Insurance Portability and Accountability Act of 1996 (HIPAA) Privacy Rule. The following safeguards will be in place to protect the privacy of the individuals who are the subjects of the health information to be used in the research and the confidentiality of that information:

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

14. PUBLICATION POLICY

The investigator shall have the right to publish the results of the study. Unless mutually agreed upon in writing, prior to submission for publication of any manuscript, poster, presentation, abstract or other written or oral material describing the results of the study, the investigator shall allow sponsor to review manuscript, poster presentation, abstract or other written or oral material which describes the results of the study for the purpose only of determining if any patentable information is disclosed. At the sponsor's request, the investigator shall withhold any publication or presentation to permit sponsor to seek patent protection and to remove any confidential information from all publications.

The International Committee of Medical Journal Editors (ICMJE) member journals have adopted a trials registration policy as a condition for publication. This policy requires that all clinical trials be registered in a public trials registry such as ClinicalTrials.gov, which is sponsored by the National Library of Medicine. It is the responsibility of the sponsor to register this trial in ClinicalTrials.gov. Any clinical trial starting enrollment after September 27, 2007 must be registered either on or before the onset of patient enrollment.

REFERENCES

1. [REDACTED]
2. [REDACTED]
3. [REDACTED]
4. [REDACTED]
5. [REDACTED]
6. [REDACTED]
7. [REDACTED]
8. [REDACTED]
9. [REDACTED]
10. [REDACTED]
11. [REDACTED]
12. [REDACTED]
13. [REDACTED]
14. [REDACTED]
15. [REDACTED]

■

[REDACTED]

■

[REDACTED]


■


[REDACTED]

Cutera, Inc.

Protocol # C-17-EV12

“Open-label, Prospective, Single-Center Feasibility Study to Evaluate the Cutera excel V™ Laser with Green Genesis and a Micro-Lens Array Attachment as compared to the standard-of-care with an excel V™ Laser”






Cutera, Inc.

Protocol # C-17-EV12


“Open-label, Prospective, Single-Center Feasibility Study to Evaluate the Cutera excel V™ Laser with Green Genesis and a Micro-Lens Array Attachment as compared to the standard-of-care with an excel V™ Laser”



Cutera, Inc.

Protocol # C-17-EV12


“Open-label, Prospective, Single-Center Feasibility Study to Evaluate the Cutera excel V™ Laser with Green Genesis and a Micro-Lens Array Attachment as compared to the standard-of-care with an excel V™ Laser”



Cutera, Inc.

Protocol # C-17-EV12


“Open-label, Prospective, Single-Center Feasibility Study to Evaluate the Cutera excel V™ Laser with Green Genesis and a Micro-Lens Array Attachment as compared to the standard-of-care with an excel V™ Laser”



Cutera, Inc.

Protocol # C-17-EV12


“Open-label, Prospective, Single-Center Feasibility Study to Evaluate the Cutera excel V™ Laser with Green Genesis and a Micro-Lens Array Attachment as compared to the standard-of-care with an excel V™ Laser”



Cutera, Inc.

Protocol # C-17-EV12

“Open-label, Prospective, Single-Center Feasibility Study to Evaluate the Cutera excel V™ Laser with Green Genesis and a Micro-Lens Array Attachment as compared to the standard-of-care with an excel V™ Laser”



Cutera, Inc.

Protocol # C-17-EV12

“Open-label, Prospective, Single-Center Feasibility Study to Evaluate the Cutera excel V™ Laser with Green Genesis and a Micro-Lens Array Attachment as compared to the standard-of-care with an excel V™ Laser”

